RxDoctor Payments Data

Jennifer Salansky, MD

Family Medicine · Largo, FLNPI 1932195005

Payments from drug & device makers

$5,158in general payments, 2019–2025

Across 250 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$959
  • Novo Nordisk$864
  • AstraZeneca$447
  • Amgen$435
  • Pfizer$381
  • Phathom Pharmaceuticals, Inc.$314
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,158100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,158 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$132,832
Medicare patients
377
Services billed
1,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$104,446
JardianceEmpagliflozin64$58,620
FarxigaDapagliflozin Propanediol25$29,093
EliquisApixaban20$24,022
JanuviaSitagliptin Phosphate24$22,880
TrulicityDulaglutide19$18,414
RybelsusSemaglutide11$16,183
MyrbetriqMirabegron13$15,194
XareltoRivaroxaban15$14,243
MounjaroTirzepatide13$13,633
VascepaIcosapent Ethyl17$10,563
KerendiaFinerenone12$8,495
SynthroidLevothyroxine Sodium66$5,380
Atorvastatin Calcium692$5,346
Rosuvastatin Calcium396$5,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$864$120,629103 claims
Lilly USA, LLCTrulicity, Mounjaro$283$32,04732 claims
AstraZenecaFarxiga$447$29,09325 claims
PfizerEliquis$381$24,02220 claims
MerckJanuvia$42$22,88024 claims
BayerKerendia$291$8,49512 claims
AbbVieSynthroid$959$5,38066 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →